Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease.

Area of Science:

• Cardiology
• Biochemistry
• Pathology

Background:

• Hypertension is associated with cardiovascular complications, including myocardial fibrosis.
• Collagen type I synthesis marker, carboxy-terminal propeptide of procollagen type I (PIP), is a potential indicator of fibrosis.
• The relationship between serum PIP and myocardial fibrosis in essential hypertension requires further investigation.

Purpose of the Study:

• To investigate the correlation between serum PIP concentrations and myocardial collagen content in patients with essential hypertension.
• To assess the potential of serum PIP as a biomarker for detecting severe myocardial fibrosis in this population.

Main Methods:

• Study included 26 hypertensive patients without ischemic cardiomyopathy.
• Endomyocardial biopsies were analyzed for collagen volume fraction (CVF) using automated image analysis.
• Serum PIP levels were measured via radioimmunoassay.

Main Results:

• Hypertensive patients exhibited significantly higher serum PIP and CVF compared to normotensives (P<0.001).
• A direct correlation was observed between CVF and serum PIP (r=0.471, P<0.02).
• Serum PIP levels were significantly higher in patients with severe fibrosis (P<0.05) and a cutoff of 127 microg/L predicted severe fibrosis with 75% sensitivity and 78% specificity.

Conclusions:

• Serum PIP concentration is strongly correlated with myocardial collagen content in essential hypertension.
• Serum PIP determination may serve as a non-invasive method for screening and diagnosing severe myocardial fibrosis in hypertensive patients.